OBSERVE MEDICAL ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  2.1% 3.4% 9.4% 13.0% 18.8%  
Credit score (0-100)  69 54 25 17 6  
Credit rating  A BBB BB BB B  
Credit limit (kDKK)  -0.1 0.0 0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  329 333 -52.8 -99.0 2,767  
EBITDA  329 333 -52.8 -467 -918  
EBIT  -364 -308 -577 -877 -1,182  
Pre-tax profit (PTP)  -23.5 6,389.9 -580.5 -891.9 -1,290.0  
Net earnings  -23.5 6,389.9 -580.5 -891.9 -1,290.0  
Pre-tax profit without non-rec. items  -23.5 6,390 -581 -892 -1,290  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  -1,514 1,389 808 -83.7 -1,374  
Interest-bearing liabilities  18,394 0.0 11.0 546 1,880  
Balance sheet total (assets)  16,994 1,414 911 888 2,019  

Net Debt  18,322 -54.2 11.0 241 1,801  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  329 333 -52.8 -99.0 2,767  
Gross profit growth  0.0% 1.3% 0.0% -87.5% 0.0%  
Employees  0 0 0 0 2  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 -367.9 -3,685.1  
Balance sheet total (assets)  16,994 1,414 911 888 2,019  
Balance sheet change%  1.6% -91.7% -35.6% -2.5% 127.4%  
Added value  329.1 333.3 -52.8 15.7 2,767.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -764 -901 -973 -805 -527  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -4.0 -5.0 -5.0 -5.0 -5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  -110.7% -92.4% 1,093.1% 885.3% -42.7%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  4.6% 78.9% -49.6% -93.2% -54.1%  
ROI %  4.6% 79.4% -52.2% -128.4% -97.4%  
ROE %  -0.1% 69.5% -52.8% -105.2% -88.8%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  -8.2% 98.2% 88.7% -8.6% -40.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  5,567.2% -16.3% -20.8% -51.7% -196.3%  
Gearing %  -1,215.0% 0.0% 1.4% -652.4% -136.8%  
Net interest  0 0 0 0 0  
Financing costs %  4.8% 16.0% 69.7% 5.5% 8.9%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 2.2 0.0 0.4 0.0  
Current Ratio  0.0 2.2 0.0 0.4 0.0  
Cash and cash equivalent  71.7 54.2 0.0 304.6 78.5  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -17,956.9 29.4 -102.5 -599.2 -3,230.2  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 1,384  
Employee expenses / employee  0 0 0 0 -1,843  
EBITDA / employee  0 0 0 0 -459  
EBIT / employee  0 0 0 0 -591  
Net earnings / employee  0 0 0 0 -645